23andMe IPF Research Study

NCT05028894 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 690

Last updated 2024-12-09

No results posted yet for this study

Summary

The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.

Conditions

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • 23andMe, Inc.

    lead INDUSTRY

Principal Investigators

  • Suyash Shringarpure · 23andMe, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-05
Primary Completion
2023-05-05
Completion
2023-05-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028894 on ClinicalTrials.gov